Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intravenous immunoglobulin + rituximab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination therapy of intravenous immunoglobulin (IVIG) and rituximab. IVIG is a blood product containing pooled human immunoglobulins (antibodies) used to modulate immune responses in various autoimmune and inflammatory diseases. Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B lymphocytes. By binding to CD20, rituximab depletes B cells through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. This combination is used off-label for certain autoimmune disorders—such as immune thrombocytopenia or some neurological conditions—where both broad immune modulation (by IVIG) and targeted B-cell depletion (by rituximab) are desired[2][3][5][6]. Rituximab was developed by Genentech/Biogen Idec.
- Other names
- IVIG
02
Targets
CD20 (B-lymphocyte antigen CD20)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on intravenous immunoglobulin + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intravenous immunoglobulin + rituximab.